Evidence map›Paper›PMID 41777155›Full record

ArticleJournal of chemical information and modeling2026

Fine-Tuning DiffDock-L for Allosteric Kinase Docking.

Eric Chen, Justin Green, Yingkai Zhang

Abstract read
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eric ChenDepartment of Chemistry, New York University, New York, New York 10003, United States.
Justin GreenDepartment of Biology, New York University, New York, New York 10003, United States.
Yingkai ZhangSimons Center for Computational Physical Chemistry at New York University, New York, New York 10003, United States.ORCID 0000-0002-4984-3354

Funding

Computational modulator design and machine learning to target protein-protein interactionsR35GM127040 · NIGMS · NEW YORK UNIVERSITY · PI Yingkai Zhang · 2018 to 2026
$4.6M
NIGMS NIH HHS R35 GM127040
6 · The paper itself

Abstract

Allosteric kinase inhibitors are an important modality for overcoming resistance and achieving selectivity, yet most structure-based docking and deep generative models are trained predominantly on orthosteric protein-ligand complexes. As a result, current methods often misplace allosteric kinase ligands into the adenosine triphosphate (ATP)-binding site and fail to recover the correct binding mode. Here we curate AlloSet, a kinome-wide, time-split data set of kinase-ligand complexes annotated by binding mode, to systematically evaluate and fine-tune the diffusion-based docking model DiffDock-L for allosteric pose prediction. We explore several fine-tuning strategies, including increased dropout, freezing of torsion parameters with translation/rotation-only fine-tuning, and molecular dynamics-based supersampling of receptor conformations and ligand poses. The resulting DiffDock-L-Allo model is found to markedly improve pose-recovery metrics for Type III/IV allosteric binders while preserving the performance on ATP-site ligands. Binding-mode-resolved evaluations and comparisons with cofolding models such as AlphaFold3 and Boltz-2 highlight how targeted retraining reshapes the generative model's sampling distribution, offering practical guidance for adapting AI-driven docking to challenging, low-data binding modes in kinase structure-based drug design.

Indexed as

Molecular Docking SimulationProtein Kinase InhibitorsProtein KinasesAdenosine TriphosphateAllosteric RegulationLigandsMolecular Dynamics SimulationProtein ConformationAdenosine TriphosphateLigandsProtein Kinase InhibitorsProtein Kinases

Identifiers

PMID41777155
PMCPMC13014456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.